Wellington Management, the top Bristol-Myers Squibb's shareholder, stated it would not support the US drugmaker's $74B worth takeover of the biotech firm Celgene.
Wellington Management, the top Bristol-Myers Squibb's shareholder, stated it would not support the US drugmaker's $74B worth takeover of the biotech firm Celgene.